Tagraxofusp
Tagraxofusp-erzs is a drug for the treatment of blastic plasmacytoid dendritic cell neoplasm. It was approved for use in the United States in 2018.
Tagraxofusp-erzs is a fusion protein consisting of interleukin 3 fused to diphtheria toxin. The fusion protein readily kills cultured pDC by binding to their IL-3 receptors to thereby gain entrance to the cells and then blocking these cells' protein synthesis.
